Shanghai Shyndec Pharmaceutical (SHSE:600420) First Quarter 2024 ResultsKey Financial Results Revenue: CN¥3.12b (down 8.6% from 1Q 2023). Net income: CN¥331.3m (up 85% from 1Q 2023). Profit margin: 11% (up from 5.2% in 1Q 2023). The increase in margin was driven by lower expenses. EPS: CN¥0.25 (up from CN¥0.15 in 1Q 2023). SHSE:600420 Earnings and Revenue Growth May 2nd 2024 All figures shown in the chart above are for the trailing 12 month (TTM) period Shanghai Shyndec Pharmaceutical…
Read More…
Shanghai Shyndec Pharmaceutical First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
